Sugi Predict

Sugi Predict / Targets / VRK1

VRK1

Serine/threonine-protein kinase VRK1 · Q99986 · VRK1 on Sugi Atlas →

1,208 patent compounds predicted against VRK1, 406 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL17780349 SCHEMBL17780349 0.68 17/20
SCHEMBL21467544 SCHEMBL21467544 0.65 17/20
SCHEMBL17780339 SCHEMBL17780339 0.56 16/20
SCHEMBL17780366 SCHEMBL17780366 0.53 16/20
SCHEMBL17780545 SCHEMBL17780545 0.51 16/20
SCHEMBL17780354 SCHEMBL17780354 0.50 16/20
SCHEMBL17780578 SCHEMBL17780578 0.50 16/20
SCHEMBL13881333 SCHEMBL13881333 1.00 15/20
SCHEMBL30013787 SCHEMBL30013787 1.00 15/20
SCHEMBL17257954 SCHEMBL17257954 0.80 15/20
SCHEMBL17780473 SCHEMBL17780473 0.77 15/20
SCHEMBL28395290 SCHEMBL28395290 0.69 15/20
SCHEMBL17780534 SCHEMBL17780534 0.54 15/20
SCHEMBL17780467 SCHEMBL17780467 0.52 15/20
SCHEMBL17257955 SCHEMBL17257955 0.76 14/20
SCHEMBL23252198 SCHEMBL23252198 0.65 14/20
SCHEMBL31060634 SCHEMBL31060634 0.64 13/20
SCHEMBL14457014 SCHEMBL14457014 0.55 13/20
SCHEMBL12345552 SCHEMBL12345552 0.53 13/20
SCHEMBL17780459 SCHEMBL17780459 0.52 13/20

Clinical trials — most relevant to VRK1 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Weight Loss Study: Genetics and Response to Naltrexone/Bupropion PHASE4RECRUITING
The G Protein-Coupled Receptor Kinase Type 2 Inhibitor Paroxetine as Adjunctive Therapy to Improve Insulin Sensitivity in Patients With Type 2 Diabetes Mellitus PHASE3UNKNOWN
Study on Safety and Efficacy of Favipiravir (Favipira) for COVID-19 Patient in Selected Hospitals of Bangladesh PHASE2/PHASE3UNKNOWN
A Phase II Study of EVEROLIMUS in Patients With Primary or Relapsed Chondrosarcomas PHASE2SUSPENDED
Immunomodulating Therapy and Improved Vaccination Responses by Cox-2 Inhibitor in HIV-infected Patients PHASE2COMPLETED
Autologous Cytokine Induced Killer Cells (CIK) for Chronic Myeloid Leukemia (CML) Patients on Standard Drug Therapy PHASE2COMPLETED
Everolimus for Children With Recurrent or Progressive Ependymoma PHASE2COMPLETED
Avelumab in Relapsed or Refractory Extranodal Natural Killer/T-cell Lymphoma[AVENT STUDY] PHASE2UNKNOWN
Effects of Roflumilast on Insulin and Blood Sugar Levels in Prediabetic Overweight and Obese Individuals PHASE1/PHASE2COMPLETED
Study of Sorafenib and Docetaxel in Metastatic Prostate Cancer PHASE2COMPLETED
Safety and Efficacy of the Fully Humanized Anti - VEGF Monoclonal Antibody LYN00101 PHASE1WITHDRAWN
BEP Study Phase I (Bevacizumab, Everolimus, Panitumumab) PHASE1COMPLETED
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma PHASE1COMPLETED
Chinese Herbal Formulation PHY906 and Sorafenib Tosylate in Treating Patients With Advanced Liver Cancer PHASE1COMPLETED
FORTRAS: A Study of MSK-TCR5 in People With Solid Tumor Cancers PHASE1RECRUITING
AZD1775 Continued Access Study to Assess Safety and Tolerability for Patients Enrolled in AZD1775 Clinical Pharmacology Studies PHASE1COMPLETED
Pre-Surgical Trial of the Combination of Metformin and Atorvastatin in Newly Diagnosed Operable Breast Cancer EARLY_PHASE1COMPLETED
Defining the Triple Negative Breast Cancer Kinome Response to GSK1120212 EARLY_PHASE1COMPLETED
Association Between Intakes of Protein, Calcium and Milk With Gene Expression and Linear Growth of School Aged Children nanCOMPLETED
Pilot Trial of Sirolimus/MEC in High Risk Acute Myelogenous Leukemia (AML) nanCOMPLETED
Regulation of Lymphocyte Anti-tumor Response in Metastatic Patients Treated With the mTOR Inhibitor Everolimus nanCOMPLETED
Dried Fruit and Postprandial Glycemia Trial nanUNKNOWN
Dietary Ketosis: Fatty Acids Activate AMPK Energy Circuits Modulating Global Methylation nanCOMPLETED
Biomarkers in Blood and Tissue Samples From Patients With Epstein-Barr Virus-Positive Hodgkin Lymphoma nanCOMPLETED
p-AKT Expression on Clinical Outcomes in Malignant Lymphoma nanCOMPLETED
Glycine and Magnesium+Thiamine for the Treatment of Primary Ciliary Dyskinesia nanRECRUITING
Protein Intake and Step Reduction in Older Adults nanCOMPLETED
Role of Nitric Oxide in Diabetic Patients With Erectile Dysfunction nanCOMPLETED
The Effect Of DAAs on miRNA-122 And Insulin Resistance In Chronic HCV Patients nanUNKNOWN
Clinical, Genetic, and Epidemiologic Study of Children and Adults With RASopathies nanRECRUITING

Related proteins — ESM-2 sequence neighbours (a VRK1 binder may also engage these)

ProteinNameSimilarity
Q32PI1 — 0.998 Q32PI1 →
Q7ZUS1 — 0.987 Q7ZUS1 →
Q80X41 — 0.986 Q80X41 →
Q8BN21 — 0.969 Q8BN21 →
A0A0E0S0W9 — 0.962 A0A0E0S0W9 →
Q8C4X2 — 0.962 Q8C4X2 →
Q8BVP5 — 0.962 Q8BVP5 →
VRK2 Serine/threonine-protein kinase VRK2 0.961 landscape →
CSNK1G2 Casein kinase I isoform gamma-2 0.960 landscape →
Q62762 — 0.960 Q62762 →
G5EI58 — 0.959 G5EI58 →
Q39050 — 0.959 Q39050 →
Q62761 — 0.958 Q62761 →
Q4R9A9 — 0.958 Q4R9A9 →
A0A0J9UVX2 — 0.957 A0A0J9UVX2 →
Q5R606 — 0.957 Q5R606 →
Q8BPM2 — 0.957 Q8BPM2 →
P40233 — 0.956 P40233 →
F4IVI0 — 0.956 F4IVI0 →
Q93Z18 — 0.956 Q93Z18 →
Q5RC72 — 0.956 Q5RC72 →
Q5BP74 — 0.956 Q5BP74 →
CSNK1E Casein kinase I isoform epsilon 0.956 landscape →
Q6P647 — 0.955 Q6P647 →
HSPH1 Heat shock protein 105 kDa 0.955 landscape →
MAP4K5 Mitogen-activated protein kinase kinase kinase kinase 5 0.955 landscape →
Q7T2E3 — 0.955 Q7T2E3 →
CSNK1A1L Casein kinase I isoform alpha-like 0.954 landscape →
Q0IIM3 — 0.954 Q0IIM3 →
P40235 — 0.954 P40235 →